Science | Nature | Cell | View More
Natural Products
Capecitabine
Capecitabine
ChemFaces products have been cited in many studies from excellent and top scientific journals
Product Name Capecitabine
Price: $30 / 20mg
CAS No.: 154361-50-9
Catalog No.: CFN90006
Molecular Formula: C15H22FN3O6
Molecular Weight: 359.35 g/mol
Purity: >=98%
Type of Compound: Alkaloids
Physical Desc.: Powder
Source:
Solvent: DMSO, Pyridine, Methanol, Ethanol, etc.
Download: COA    MSDS    SDF
Similar structural: Comparison (Web)  (SDF)
Guestbook:
Contact Us
Order & Inquiry & Tech Support

Tel: (0086)-27-84237683
Tech: service@chemfaces.com
Order: manager@chemfaces.com
Address: 176, CheCheng Eest Rd., WETDZ, Wuhan, Hubei 430056, PRC
How to Order
Orders via your E-mail:

1. Product number / Name / CAS No.
2. Delivery address
3. Ordering/billing address
4. Contact information
Order: manager@chemfaces.com
Delivery time
Delivery & Payment method

1. Usually delivery time: Next day delivery by 9:00 a.m. Order now

2. We accept: Wire transfer & Credit card & Paypal
Citing Use of our Products
* Packaging according to customer requirements(5mg, 10mg, 20mg and more). We shipped via FedEx, DHL, UPS, EMS and others courier.
According to end customer requirements, ChemFaces provide solvent format. This solvent format of product intended use: Signaling Inhibitors, Biological activities or Pharmacological activities.
Size /Price /Stock 10 mM * 1 mL in DMSO / $10.8 / In-stock
Other Packaging *Packaging according to customer requirements(100uL/well, 200uL/well and more), and Container use Storage Tube With Screw Cap
Our products had been exported to the following research institutions and universities, And still growing.
  • Leibniz Institute of Plant Bioc... (Germany)
  • University of Indonesia (Indonesia)
  • Vin?a Institute of Nuclear Scie... (Serbia)
  • University of Liège (Belgium)
  • Korea Intitute of Science and T... (Korea)
  • University of Vigo (Spain)
  • Chulalongkorn University (Thailand)
  • Ateneo de Manila University (Philippines)
  • University of Hull (United Kingdom)
  • Osmania University (India)
  • Ain Shams University (Egypt)
  • More...
Package
Featured Products
Ginsenoside Rb2

Catalog No: CFN99965
CAS No: 11021-13-9
Price: $100/20mg
Oroxylin A

Catalog No: CFN98540
CAS No: 480-11-5
Price: $80/20mg
Phyllanthin

Catalog No: CFN99050
CAS No: 10351-88-9
Price: $288/10mg
Isorhamnetin

Catalog No: CFN98735
CAS No: 480-19-3
Price: $60/20mg
Dehydropachymic acid

Catalog No: CFN92742
CAS No: 77012-31-8
Price: $268/10mg
Meloside A

Catalog No: CFN90132
CAS No: 60767-80-8
Price: $238/5mg
Luteolin 7-rutinoside

Catalog No: CFN93556
CAS No: 20633-84-5
Price: $218/20mg
Perillen

Catalog No: CFN90862
CAS No: 539-52-6
Price: $168/20mg
Isofraxidin

Catalog No: CFN90181
CAS No: 486-21-5
Price: $40/20mg
Terpineol

Catalog No: CFN92688
CAS No: 98-55-5
Price: $30/20mg
Related Screening Libraries
Size /Price /Stock 10 mM * 100 uL in DMSO / Inquiry / In-stock
10 mM * 1 mL in DMSO / Inquiry / In-stock
Related Libraries
Biological Activity
Description: Capecitabine-induced leukocytoclastic vasculitis under neoadjuvant chemotherapy for locally advanced colorectal cancer.
In vivo:
J Gastrointest Oncol. 2015 Jun;6(3):E40-3.
Capecitabine-induced leukocytoclastic vasculitis under neoadjuvant chemotherapy for locally advanced colorectal cancer.[Pubmed: 26029464]
We describe a case of Capecitabine-induced leukocytoclastic vasculitis in a patient with locally advanced rectal cancer under curative neoadjuvant concurrent chemoradiation using Capecitabine.
METHODS AND RESULTS:
After 5 days of the initiation of Capecitabine the patient developed a pruritic maculopapular rash in her extremities consistent with vasculitis which was confirmed on skin biopsy without any signs of systemic involvement. Capecitabine was held and the rash was treated with topical steroids with complete resolution of both rash and pruritus. Due to a lack of other alternative chemotherapeutic options and the cutaneous-only involvement of vasculitis, the Capecitabine was re-introduced. Two days later, the patient developed an identical maculopapular rash with a similar distribution. Prednisone was initiated while the Capecitabine was continued with complete resolution of the rash. The patient successfully completed her curative neoadjuvant chemoradiation therapy treatment without the need to permanently discontinue the Capecitabine.
Curr Med Res Opin. 2015 Apr;31(4):731-41.
Observational study of adjuvant therapy with capecitabine in colon cancer.[Pubmed: 25651480]
This observational study was conducted to document the safety of Capecitabine-based adjuvant therapy in patients with resected colon cancer under routine clinical conditions.
METHODS AND RESULTS:
ML20431 was a prospective, multicenter, non-interventional, observational study. It was designed to answer five research questions relating to safety, dosage and administration, and discontinuation from Capecitabine-based adjuvant therapy. Patients were required to have R0 resected stage III colon cancer and have started treatment with Capecitabine-based adjuvant therapy based on a decision by the investigator. Patients were followed over an observation period of ≤6 months after initiation of therapy. Investigators were required to complete the study case report form at study entry, each treatment cycle, and at the final examination. A total of 1485 patients were included in the study, and 1481 patients were treated with Capecitabine and formed the analysis population. Most patients had colon cancer (78.3%), followed by rectal cancer (16.4%). Most patients had stage III disease (69.3%); the remaining patients had stage II disease (30.7%). The most common all-grade adverse reactions were hand-foot syndrome (46.9%), diarrhea (34.4%), and hemoglobin decreases (31.5%). Grade 3/4 adverse reactions were infrequent (<4%). Serious adverse events were reported in 96 patients (6.5%). Six or more cycles of treatment were completed by 77.9% of patients. Approximately two-thirds of patients (67.3%) received Capecitabine monotherapy and the remainder (32.7%) received Capecitabine in combination with ≥1 drugs, most commonly oxaliplatin (460 cases). Discontinuation of Capecitabine was documented in 344 patients (23.2%). no efficacy data were collected; the questionnaires for patients' expectations and satisfaction were not formally validated; and a few patients (<1.5%) had some retrospective data.
CONCLUSIONS:
The safety profile of Capecitabine-based adjuvant therapy in a broad patient population with colon cancer is similar to that previously documented in phase III clinical trials.
Anticancer Res. 2014 Dec;34(12):7239-45.
Concomitant capecitabine with hepatic delivery of drug eluting beads in metastatic colorectal cancer.[Pubmed: 25503155]
Effectiveness and toxicity of transcatheter arterial injection of irinotecan-eluting beads (DEBIRI) with and without concurrent Capecitabine in pre-treated patients with metastatic colorectal cancer (CRC).
METHODS AND RESULTS:
An Institutional Review Board-approved, multi-institutional registry from 5/2008 to 8/2013 was reviewed. Patients who received DEBIRI with (X-DEBIRI) or without (DEBIRI) Capecitabine were compared. Twenty-two X-DEBIRI and 149 DEBIRI patients were compared. There was no difference in the two groups with regards to adverse events (p=0.56). During a 3- and 6-month evaluation, the disease control rate (DCR) was similar in both groups. During the 12-month evaluation, there was better DCR in the X-DEBIRI group (p=0.03). Median survival was 13 months in the DEBIRI group and 22 months in the X-DEBIRI group (log-rank test, p=0.217).
CONCLUSIONS:
There is no additional toxicity when adding Capecitabine with DEBIRI. Concurrent Capecitabine may offer more durable disease control rate compared to DEBIRI-alone. Survival benefit with concurrent Capecitabine was not statistically significant but there may be a trend towards improved survival.
Capecitabine Description
Source:
Solvent: DMSO, Pyridine, Methanol, Ethanol, etc.
Storage: Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

After receiving: The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
ChemFaces New Products and Compounds
Kidjolanin

Catalog No: CFN95503
CAS No: 38395-01-6
Price: $318/5mg
3''-Galloylquercitrin

Catalog No: CFN95048
CAS No: 503446-90-0
Price: $368/5mg
Massonianoside D

Catalog No: CFN95500
CAS No: 85115-04-4
Price: $318/10mg
Astin C

Catalog No: CFN95189
CAS No: 148057-23-2
Price: $318/10mg
Silychristin B

Catalog No: CFN95160
CAS No: 879325-58-3
Price: $318/5mg
Daucoidin A

Catalog No: CFN95275
CAS No: 103629-87-4
Price: $318/5mg
3',8-Dihydroxyvestitol

Catalog No: CFN95384
CAS No: 122587-87-5
Price: $413/5mg
Methyl ganoderate B

Catalog No: CFN95551
CAS No: 81907-65-5
Price: $413/5mg
Recently, ChemFaces products have been cited in many studies from excellent and top scientific journals

Cell. 2018 Jan 11;172(1-2):249-261.e12.
doi: 10.1016/j.cell.2017.12.019.
IF=36.216(2019)

PMID: 29328914

Cell Metab. 2020 Mar 3;31(3):534-548.e5.
doi: 10.1016/j.cmet.2020.01.002.
IF=22.415(2019)

PMID: 32004475

Mol Cell. 2017 Nov 16;68(4):673-685.e6.
doi: 10.1016/j.molcel.2017.10.022.
IF=14.548(2019)

PMID: 29149595

ACS Nano. 2018 Apr 24;12(4): 3385-3396.
doi: 10.1021/acsnano.7b08969.
IF=13.903(2019)

PMID: 29553709

Nature Plants. 2016 Dec 22;3: 16206.
doi: 10.1038/nplants.2016.205.
IF=13.297(2019)

PMID: 28005066

Sci Adv. 2018 Oct 24;4(10): eaat6994.
doi: 10.1126/sciadv.aat6994.
IF=12.804(2019)

PMID: 30417089
Calculate Dilution Ratios(Only for Reference)
1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.7828 mL 13.914 mL 27.828 mL 55.656 mL 69.5701 mL
5 mM 0.5566 mL 2.7828 mL 5.5656 mL 11.1312 mL 13.914 mL
10 mM 0.2783 mL 1.3914 mL 2.7828 mL 5.5656 mL 6.957 mL
50 mM 0.0557 mL 0.2783 mL 0.5566 mL 1.1131 mL 1.3914 mL
100 mM 0.0278 mL 0.1391 mL 0.2783 mL 0.5566 mL 0.6957 mL
* Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
Ginsenoside Rb2

Catalog No: CFN99965
CAS No: 11021-13-9
Price: $100/20mg
Oroxylin A

Catalog No: CFN98540
CAS No: 480-11-5
Price: $80/20mg
Phyllanthin

Catalog No: CFN99050
CAS No: 10351-88-9
Price: $288/10mg
Isorhamnetin

Catalog No: CFN98735
CAS No: 480-19-3
Price: $60/20mg
Dehydropachymic acid

Catalog No: CFN92742
CAS No: 77012-31-8
Price: $268/10mg
Meloside A

Catalog No: CFN90132
CAS No: 60767-80-8
Price: $238/5mg
Luteolin 7-rutinoside

Catalog No: CFN93556
CAS No: 20633-84-5
Price: $218/20mg
Perillen

Catalog No: CFN90862
CAS No: 539-52-6
Price: $168/20mg
Isofraxidin

Catalog No: CFN90181
CAS No: 486-21-5
Price: $40/20mg
Terpineol

Catalog No: CFN92688
CAS No: 98-55-5
Price: $30/20mg
Tags: buy Capecitabine | Capecitabine supplier | purchase Capecitabine | Capecitabine cost | Capecitabine manufacturer | order Capecitabine | Capecitabine distributor